The PIONEER-01 Pivotal Study of the Imagio Breast Imaging System

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2013 by Seno Medical Instruments Inc.
Sponsor:
Information provided by (Responsible Party):
Seno Medical Instruments Inc.
ClinicalTrials.gov Identifier:
NCT01943916
First received: September 12, 2013
Last updated: September 16, 2013
Last verified: September 2013
  Purpose

Imagio is a multi-modality device, comprised of opto-acoustic (OA) imaging co-registered with diagnostic grey-scale (B mode) ultrasound, that has been designed to concurrently collect OA images in conjunction with diagnostic grey-scale (B-mode) ultrasound.

Imagio is expected to identify two functional hallmarks of a potential malignancy: the presence of abnormal blood vessels (angiogenesis); and the relative reduction in oxygen content of hemoglobin. The technology is non-invasive and does not require any contrast agent or radio-isotope, which is required for other modalities such as MRI or PET.

This is a prospective, single arm, controlled, multi-center, observational study that will compare Imagio versus conventional diagnostic ultrasound (CDU) for the visualization of suspicious masses.


Condition Intervention
Breast Cancer
Device: Imagio Scan

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: A Pivotal Study of Imaging With Opto-acoustics to Diagnose Breast Masses Detected by Mammography and/or Diagnostic Ultrasound: A New Evaluation Tool for Radiologists

Resource links provided by NLM:


Further study details as provided by Seno Medical Instruments Inc.:

Primary Outcome Measures:
  • The primary outcome measure is the test of sensitivity and specificity of Imagio vs. standard of care ultrasound in breast lesions based on the probability of malignancy (POM). [ Time Frame: The primary endpoint is evaluated prior to biopsy for subjects with a positive-diagnostic ultrasound, and is evaluated at 12-months for subjects with a negative-diagnostic ultrasound. ] [ Designated as safety issue: No ]

Estimated Enrollment: 2000
Study Start Date: July 2013
Estimated Study Completion Date: January 2015
Estimated Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Imagio scan
Female subjects with a recently identified lesion for which a diagnostic work-up is necessary.
Device: Imagio Scan

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

A total of 2,000 female subjects who have a recently identified lesion for which further diagnostic work-up is necessary.

Criteria

Inclusion Criteria:

  • female
  • 18 years of age or older
  • suspicious mass of breast, identified by a health care practitioner within the past 30 days with diagnostic methodology other than conventional ultrasound.

Exclusion Criteria:

  • presence of a condition or impediment that may interfere with imaging.
  • pregnant or lactating
  • undergoing neoadjuvant therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01943916

Contacts
Contact: Janet Campbell, CEO (210) 576 - 1270 pioneerstudy@senomedical.com

Locations
United States, District of Columbia
Georgetown University Hospital, Department of Radiology Recruiting
Washington, District of Columbia, United States, 20007
Contact: Erini Makariou, MD         
Principal Investigator: Erini Makariou, MD         
United States, Ohio
Cleveland Clinic, Breast Services DDI Clinical Research Recruiting
Cleveland, Ohio, United States, 44195
Contact: Steven Grobmeyer, MD         
Principal Investigator: Steven Grobmeyer, MD         
United States, Texas
MD Anderson Cancer Center, Department of Radiology and Breast Imaging Recruiting
Houston, Texas, United States, 77030
Contact: Basak Dogan, MD         
Principal Investigator: Basak Dogan, MD         
Univ. Texas Health Science Center at San Antontio, Breast Imaging Center at the Cancer Therapy Research Center Recruiting
San Antonio, Texas, United States, 78229
Contact: Ken Kist, MD         
Principal Investigator: Ken Kist, MD         
Sponsors and Collaborators
Seno Medical Instruments Inc.
Investigators
Study Director: A. Thomas Stavros, MD Chief Medical Officer, Seno Medical Instruments, Inc.
  More Information

Additional Information:
Publications:
Otto P, Kist K, Dornbluth NC, McCorvey BM, Zalev J, Herzog D, Clingman B, Miller T, Ermilov S, Nadvoretsky V, Conjusteau A, Su R, Oraevsky A. Clinical Feasibility Study of Combined Opto-Acoustic and Ultrasonic Imaging Modality Providing Co-registered Functional and Anatomical Maps of Breast Tumors. Presented at: 97th Scientific Assembly and Annual Meeting of The Radiological Society of North America; 2011 Nov 28; Chicago, IL.
Otto P, Kist K, Dornbluth NC, McCorvey BM, Miller T, Herzog D, Clingman B, Zalev J, Ermilov S, Oraevsky A. Improve Differentiation of Breast Tumors Using Laser Opto-Acoustic Ultrasonic Imaging System. Poster presented at: European Congress of Radiology; 2012 Mar 1-5; Vienna, Austria.
Otto P, Kist K, Dornbluth C, Stavros T, Ulissey M, Herzog D, Clingman B, Zalev J, Lavin P, Oraevsky A. Functional Images of Hemoglobin and Blood Oxygen Saturation Co-registered with Ultrasound Provide Accurate Differentiation of Breast Tumors. Presented at: American Institute of Ultrasound in Medicine Annual Convention; 2013 Apr 6-10; New York, NY.
Zalev J, Clingman B, Smith R, Herzog D, Miller T, Stavros AT, Ermilov S, Conjusteau A, Tsyboulski D, Oraevsky A, Kist K, Dornbluth C, Otto P. Real-time Opto-acoustic Imaging System for Clinical Assessment of Breast Lesions. Presented at: Photons plus Ultrasound: Imaging and Sensing, SPIE/BiOS, Photonics West Symposium; 3 Feb 2013; San Francisco, CA.

Responsible Party: Seno Medical Instruments Inc.
ClinicalTrials.gov Identifier: NCT01943916     History of Changes
Obsolete Identifiers: NCT01937962
Other Study ID Numbers: PIONEER-01
Study First Received: September 12, 2013
Last Updated: September 16, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by Seno Medical Instruments Inc.:
breast imaging diagnosis
breast ultrasound
Imagio
Seno Medical Instruments, Inc.
Seno
opto-acoustics
OA
angiogenesis
blood map

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases

ClinicalTrials.gov processed this record on July 28, 2014